BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 27894836)

  • 1. Use of complement binding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney transplantation.
    Ramon DS; Huang Y; Zhao L; Rendulic T; Park JM; Sung RS; Samaniego M
    Hum Immunol; 2017 Feb; 78(2):57-63. PubMed ID: 27894836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Int; 2017 Apr; 30(4):347-359. PubMed ID: 27717025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
    Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
    Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Complement-binding Donor-specific Antibodies, Not IgG-antibody Strength Nor C4d Status, at Antibody-mediated Rejection Diagnosis Is an Independent Predictor of Kidney Graft Failure.
    Malheiro J; Santos S; Tafulo S; Dias L; Martins S; Fonseca I; Almeida M; Pedroso S; Beirão I; Castro-Henriques A; Cabrita A
    Transplantation; 2018 Nov; 102(11):1943-1954. PubMed ID: 29757900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
    Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
    Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure.
    Cazarote HB; Shimakura S; Valdameri JS; Contieri FLC; von Glehn CQC; Aita CM; Susin MF; Sotomaior VS; Glehn-Ponsirenas R
    Transpl Immunol; 2018 Aug; 49():33-38. PubMed ID: 29596992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Pretransplant Complement-fixing Donor-specific Antibodies Identified by C1q Assay in Kidney Transplantation.
    Thammanichanond D; Wiwattanathum P; Mongkolsuk T; Kantachuvesiri S; Worawichawong S; Vallipakorn SA; Kitpoka P
    Transplant Proc; 2016 Apr; 48(3):756-60. PubMed ID: 27234729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.
    Kuppachi S; Holanda D; Gallegos S; Field EH
    Clin Transpl; 2016; 32():127-134. PubMed ID: 28564530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
    Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
    Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically-relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation.
    Salvadé I; Aubert V; Venetz JP; Golshayan D; Saouli AC; Matter M; Rotman S; Pantaleo G; Pascual M
    Hum Immunol; 2016 Jun; 77(6):483-9. PubMed ID: 27085791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.
    Eskandary F; Bond G; Kozakowski N; Regele H; Marinova L; Wahrmann M; Kikić Ž; Haslacher H; Rasoul-Rockenschaub S; Kaltenecker CC; König F; Hidalgo LG; Oberbauer R; Halloran PF; Böhmig GA
    Transplantation; 2017 Mar; 101(3):631-641. PubMed ID: 27120452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of complement-fixing donor-specific antibodies identified by a C1q assay after heart transplantation.
    Farrero Torres M; Pando MJ; Luo C; Luikart H; Valantine H; Khush K
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28940521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
    Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
    Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
    Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison Between Total IgG, C1q, and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies.
    Moreno Gonzales MA; Mitema DG; Smith BH; Schinstock CA; Stegall MD; Wakefield LL; Henderson NA; DeGoey SR; Kreuter JD; Gandhi MJ
    Transplant Proc; 2017 Nov; 49(9):2031-2035. PubMed ID: 29149956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients.
    Zeevi A; Lunz J; Feingold B; Shullo M; Bermudez C; Teuteberg J; Webber S
    J Heart Lung Transplant; 2013 Jan; 32(1):98-105. PubMed ID: 23142561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C1q binding is not an independent risk factor for kidney allograft loss after an acute antibody-mediated rejection episode: a retrospective cohort study.
    Moktefi A; Parisot J; Desvaux D; Canoui-Poitrine F; Brocheriou I; Peltier J; Audard V; Kofman T; Suberbielle C; Lang P; Rondeau E; Grimbert P; Matignon M
    Transpl Int; 2017 Mar; 30(3):277-287. PubMed ID: 27992962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of C1q fixing donor-specific antibodies on renal transplant outcome.
    Baranwal AK; Goswami S; Agarwal SK; Kaur G; Mehra NK
    Scand J Immunol; 2021 Jul; 94(1):e13048. PubMed ID: 33914934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.